An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials

ovartis Pharma Services AG0 个研究点目标入组 0 人开始时间: 2010年2月16日最近更新: 2022年3月28日

研究概览

暂无简介。

•1. Patients who have completed at least 2 cycles of ASA404 in conjunction with a taxane-based chemotherapy in a previous Novartis-sponsored ASA404 trial and continued treatment with ASA404 alone or in combination with either docetaxel, paclitaxel, carboplatin or in combination with the paclitaxel plus carboplatin chemotherapy regimen, is considered appropriate by the Investigator.
•2. Patients must have achieved at least stable disease by radiographic criteria.
•3. Written informed consent obtained prior to any non-standard of care study procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Pregnant or breast feeding females
•2. Women of child-bearing potential or sexually active males, unwilling or unable to use the required highly effective method(s) of contraception for both sexes while receiving treatment and for at least 6 months after the discontinuation of study treatment.
•3. Patients who had an ASA404 dose within the past 21 days.
•4. Patients who have not had an ASA404 dose within the past 64 days.
•For patients being treated with docetaxel, additional exclusion criteria:
•5. Known allergy or hypersensitivity to drugs formulated with polysorbate 80 or any known excipients of these drugs.
•For patients being treated with paclitaxel, additional exclusion criteria:
•6. Known allergy or hypersensitivity to platinum-containing drugs, taxanes, other drugs formulated in Cremophor EL (polyoxyethylated castor oil) or any known excipients of these drugs.
•7. Peripheral sensory neuropathy with functional impairment (CTCAE v3.0 Grade 2
•neuropathy, regardless of causality).
•8. Patients taking oral, implantable or injectable contraceptives who are not willing or otherwise unable to use a concomitant barrier method.
•For patients being treated with carboplatin, additional exclusion criteria:
•9. Known allergy or hypersensitivity to platinum-containing drugs.

发起方